Proteins



AMA-37

Cat. No.: HY-100706 CAS No.: 404009-46-7 Molecular Formula: C₁₇H₁₇NO₃ Molecular Weight: 283.32 DNA-PK Target:

Pathway: Cell Cycle/DNA Damage; PI3K/Akt/mTOR


Storage: Powder -20°C

2 years

3 years

-80°C In solvent 6 months

> -20°C 1 month



Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (352.96 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.5296 mL	17.6479 mL	35.2958 mL
	5 mM	0.7059 mL	3.5296 mL	7.0592 mL
	10 mM	0.3530 mL	1.7648 mL	3.5296 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

BIOLOGICAL ACTIVITY

Description AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC₅₀ values of 0.27 μM (DNA-PK), 32 μM (p110 $\alpha), 3.7~\mu\text{M}$ (p110 β), and 22 μM (p110 γ), respectively $^{[1][2]}.$

IC₅₀ & Target IC50: 0.27 μM (DNA-PK)^[1].

AMA-37 inhbits PI3K poorly[2]. In Vitro

AMA-37 (20 μM) reduces the ability of UCN-01, isogranulatimide, and debromohymenialdesine, but not caffeine, to

overcome G2 arrest (ρ < 0.05)^[3].

Inhibition of DNA-PK with AMA37 leads to radiosensitization^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
- [2]. Zachary A Knight, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004 Sep 1;12(17):4749-59.
- [3]. Christopher M Sturgeon, et al. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther. 2006 Apr;5(4):885-92.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com